The South America diabetes care devices market is expected to grow from US$ 1,240.89 million in 2022 to US$ 1,712.21 million by 2028; it is estimated to grow at a CAGR of 4.1% from 2022 to 2028.
Technological advancements in the healthcare industry are encouraging market players to focus on research and development of insulin delivery devices. There are various methods to deliver insulin into the human body, including needles, insulin pens, and insulin pumps. Insulin pumps are small computerized diabetes management devices connected with a cannula under the skin to deliver a slow and continuous insulin level. Optimal diabetes management depends on accurate glucose monitoring devices. Technological advancements in glucose monitoring devices have resulted in smaller requirements for blood samples with improved accuracy. Furthermore, the ability to transfer data between the blood glucose (BG) meter and insulin delivery devices has been improved. A smart insulin pen is a reusable injector pen with an easy-to-use smartphone app that can assist diabetic people in managing insulin delivery. This intelligent device calculates and tracks doses while providing patients with helpful reminders. In November 2020, Medtronic plc launched InPen, which connects to real-time Guardian Connect CGM data. The continuous research in insulin pens supports the growth of the diabetes care devices market. Pen needles and syringes are the most used devices for injecting insulin into diabetic patients. Various manufacturers are developing innovative products to sustain themselves in the highly fragmented needle market. Moreover, the easy regulatory approvals have led to mid-sized companies entering the market and competing with the local and established players. The development of pen needles with precise lubrication to reduce the pain sensation has been another focus of manufacturers during the research. Thus, rising technological advancements and increasing influx of new products are expected to propel the market's growth during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America diabetes care devices market. The South America diabetes care devices market is expected to grow at a good CAGR during the forecast period.
South America Diabetes Care Devices Market Revenue and Forecast to 2028 (US$ Million)
South America Diabetes Care Devices Market Segmentation
The South America diabetes care devices market is segmented based on type, end user, and country. Based on type, the market is bifurcated into glucose monitoring devices and insulin delivery devices. The glucose monitoring devices segment would dominate the market in 2022. The glucose monitoring devices segment is further categorized into testing strips, glucometer, lancets, and others. Similarly, the insulin delivery devices segment is segmented into insulin pens, insulin syringes, insulin pumps, and others. Based on end user, the South America diabetes care devices market is bifurcated into homecare and hospitals & clinics. The homecare segment would dominate the market in 2022. Based on country, the market has been categorized into Brazil, Argentina, and the Rest of SAM. Brazil would dominate the market in 2022.
B. Braun Melsungen AG; BD; Dexcom, Inc.; Eli Lilly and Company.; F. Hoffmann-La Roche Ltd.; Insulet Corporation; Medtronic; Novo Nordisk A/S; Tandem Diabetes Care Inc.; and Terumo Corporation are among the leading companies in the SAM diabetes care devices market.